Abbvie-Header

Abbvie-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Praxis Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Arab Health 2021

Participation Not Confirmed

Update your events

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE

Contact the Supplier

Lead Product(s): PRAX-562

Therapeutic Area: Genetic Disease Product Name: PRAX-562

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2021

Details:

PRAX-562 is a first selective persistent sodium current blocker. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE.